ADVANCE Study: Objectives, design and current status;Etude ADVANCE: Objectifs, protocole et état actuel

Drugs

Volumn 63, Issue SPEC. ISS. 1, 2003, Pages 39-44

  Chalmers, John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLICLAZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INDAPAMIDE; PERINDOPRIL; PLACEBO; SULFONYLUREA;

ADULT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG INDICATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; VASCULAR DISEASE;

EID: 0037245096     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363991-00005     Document Type: Conference Paper

References (17)

1. ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease: preterax and diamicon MR controlled evaluation. Diabetologia 2001; 44: 1118-20
2. ADVANCE Collaborative Group. Rational and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. J Hypertens 2001; 19 Suppl. 4: S21-8
3. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12
5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
7. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9
8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53
9. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-2446
10. Guidelines Subcommittee. 1999 World Health Organisation: International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
11. Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens 1999; 21 (5 & 6): 875-84
12. Chalmers J. The use of free and fixed drug combinations to improve hypertension control in our populations. Eur Heart J 1999; 20: 1060-1
13. Chalmers J. Efficacy and acceptability of the fixed low-dose perindopril-indapamide combination as first-line therapy in hypertension. Eur Heart J 1999; 1 Suppl. L: L20-5
14. Castaigne A, Chalmers J, Morgan T, et al. Efficacy and safety of an oral fixed low-dose perindopril 2mg/indapamide 0.625mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension. Clin Exp Hypertens 1999; 21: 1097-110
15. Chalmers J. Castaigne A, Morgan T, et al. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000; 18: 327-37
16. Mogensen CE, Viberti J, Halimi S, et al. Treatment based on a low dose combination of perindopril and indapamide reduces albuminuria more effectively than enalapril in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 21A-2A
17. De Luca N, Safar ME. Efficacy of a very low dose perindopril 2mg/indapamide 0.625mg on cardiac hypertrophy in hypertensive patients. The REASON project [abstract]. J Hypertens 2002; 20 Suppl. 4: S164